Jeong-Hyun Kim1, Chansu Lee2, Hyun Sub Cheong2,3, Youngil Koh4, Kwang-Sung Ahn5, Hyung-Lae Kim6, Hyoung Doo Shin1,3,7, Sung-Soo Yoon8,9,10. 1. Research Institute for Basic Science, Sogang University, Seoul, Republic of Korea. 2. Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. 3. Department of Genetic Epidemiology, SNP Genetics Inc., Seoul, Republic of Korea. 4. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. 5. Functional Genome Institute, PDXen Biosystem Inc., Seoul, Republic of Korea. 6. Department of Biochemistry, School of Medicine, Ewha Womans University, Seoul, Republic of Korea. 7. Department of Life Science, Sogang University, Seoul, Republic of Korea. 8. Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. ssysmc@snu.ac.kr. 9. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. ssysmc@snu.ac.kr. 10. Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. ssysmc@snu.ac.kr.
Abstract
PURPOSE: The solute carrier family 29 (equilibrative nucleoside transporter), member 1 (SLC29A1) is known to be involved in the transportation and resistance of the nucleoside analog cytosine arabinoside (AraC), one of the most effective drugs in the treatment of acute myeloid leukemia (AML). METHODS: In vitro functional analysis in AML cells and genetic association study were performed. RESULTS: Our functional analysis of SLC29A1 on anticancer effects of AraC showed that cytotoxic effects of AraC in AML cell lines were decreased by the reduction of SLC29A1 expression (P < 0.05). To investigate whether SLC29A1 polymorphisms could affect the achievement of complete remission (CR) in AML, we genotyped a total of six common single nucleotide polymorphisms on SLC29A1 in 103 AML patients, including 17 successes and 86 failures in CR. As a result, rs3734703 in 3'-untranslated region was significantly associated with CR even after correction for multiple testing (Fisher's exact test, P = 0.008; P corr = 0.04). A haplotype, ht3 (A-G-G-T-C-A; frequency = 0.294 in success group; frequency = 0.120 in failure group), also revealed a significant association with CR (P = 0.01; simulated P sim = 0.02). CONCLUSIONS: Although further replication in larger subjects and further functional evaluations are required, our results suggest the contribution of SLC29A1 to cytotoxic effects of AraC. In addition, genetic variations of SLC29A1 could be a potential marker for the achievement of CR of cancers of white blood cells including AML.
PURPOSE: The solute carrier family 29 (equilibrative nucleoside transporter), member 1 (SLC29A1) is known to be involved in the transportation and resistance of the nucleoside analog cytosine arabinoside (AraC), one of the most effective drugs in the treatment of acute myeloid leukemia (AML). METHODS: In vitro functional analysis in AML cells and genetic association study were performed. RESULTS: Our functional analysis of SLC29A1 on anticancer effects of AraC showed that cytotoxic effects of AraC in AML cell lines were decreased by the reduction of SLC29A1 expression (P < 0.05). To investigate whether SLC29A1 polymorphisms could affect the achievement of complete remission (CR) in AML, we genotyped a total of six common single nucleotide polymorphisms on SLC29A1 in 103 AMLpatients, including 17 successes and 86 failures in CR. As a result, rs3734703 in 3'-untranslated region was significantly associated with CR even after correction for multiple testing (Fisher's exact test, P = 0.008; P corr = 0.04). A haplotype, ht3 (A-G-G-T-C-A; frequency = 0.294 in success group; frequency = 0.120 in failure group), also revealed a significant association with CR (P = 0.01; simulated P sim = 0.02). CONCLUSIONS: Although further replication in larger subjects and further functional evaluations are required, our results suggest the contribution of SLC29A1 to cytotoxic effects of AraC. In addition, genetic variations of SLC29A1 could be a potential marker for the achievement of CR of cancers of white blood cells including AML.
Authors: Abdelrahman H Elsayed; Xueyuan Cao; Amit K Mitra; Huiyun Wu; Susana Raimondi; Christopher Cogle; Zeina Al-Mansour; Raul C Ribeiro; Alan Gamis; Edward Anders Kolb; Richard Aplenc; Todd A Alonzo; Soheil Meshinchi; Jeffrey Rubnitz; Stanley Pounds; Jatinder K Lamba Journal: J Clin Oncol Date: 2022-01-06 Impact factor: 50.717
Authors: Juan Eduardo Megías-Vericat; David Martínez-Cuadrón; Antonio Solana-Altabella; José Luis Poveda; Pau Montesinos Journal: Pharmaceutics Date: 2022-04-17 Impact factor: 6.525
Authors: Abdelrahman H Elsayed; Xueyuan Cao; Kristine R Crews; Varsha Gandhi; William Plunkett; Jeffrey E Rubnitz; Raul C Ribeiro; Stanley B Pounds; Jatinder K Lamba Journal: Pharmacogenomics Date: 2018-08-08 Impact factor: 2.533
Authors: Sophie M Stief; Anna-Li Hanneforth; Sabrina Weser; Raphael Mattes; Michela Carlet; Wen-Hsin Liu; Michael D Bartoschek; Helena Domínguez Moreno; Matthias Oettle; Julia Kempf; Binje Vick; Bianka Ksienzyk; Belay Tizazu; Maja Rothenberg-Thurley; Hilmar Quentmeier; Wolfgang Hiddemann; Sebastian Vosberg; Philipp A Greif; Klaus H Metzeler; Gunnar Schotta; Sebastian Bultmann; Irmela Jeremias; Heinrich Leonhardt; Karsten Spiekermann Journal: Leukemia Date: 2019-06-14 Impact factor: 11.528